Bausch + Lomb Corporation BLCO
19.38 USD -1.31 (-6.33%)
Regular-session close
19.40 +0.02 +0.10%
After hours · Nov 20, 7:23 PM ET
19.30 Day range 20.50
14.56 52-week range 21.37
- YTD
- +13.47%
- 1 year
- +33.10%
News
seekingalpha.com Bausch + Lomb Corporation (BLCO) Discusses Phase II Results for BL1332 in Ocular Surface Pain Transcript Bausch + Lomb Corporation (BLCO) Discusses Phase II Results for BL1332 in Ocular Surface Pain Transcript
benzinga.com Bausch + Lomb Post-Surgery Eye Pain Drug Misses Study Goal But Shows Early Relief Bausch + Lomb reports Phase 2 data for eye pain drug BL1332, showing early relief and strong safety despite missing its primary endpoint.
reuters.com Bausch + Lomb eye-drop drug misses mid-stage study main goal Bausch + Lomb eye-drop drug misses mid-stage study main goalbenzinga.com Bausch + Lomb Reports Phase 2 Results For BL1332; Primary Endpoint Missed, Exploratory Analyses Show Pain Relief And Faster Corneal Healing Both BL1332 doses demonstrated numerically greater pain relief than vehicle across all primary, secondary and exploratory pain analyses; the primary endpoint at 24 hours was not metExploratory…
zacks.com Are Medical Stocks Lagging Bausch + Lomb (BLCO) This Year? Here is how Bausch + Lomb (BLCO) and Chemed (CHE) have performed compared to their sector so far this year.benzinga.com Barclays Maintains Overweight on Bausch & Lomb, Raises Price Target to $27 Barclays analyst Christopher Pasquale maintains Bausch & Lomb (NYSE:BLCO) with a Overweight and raises the price target from $24 to $27.
zacks.com Best Growth Stocks to Buy for November 17th EXPE, BLCO and CR made it to the Zacks Rank #1 (Strong Buy) growth stocks list on November 17th, 2026.
benzinga.com This Coinbase Analyst Turns Bearish; Here Are Top 5 Downgrades For Monday Analysts downgraded PFSI, CAMT, BLCO, COIN and FMNB; targets fell for PFSI, CAMT and COIN but rose for BLCO.benzinga.com HC Wainwright & Co. Downgrades Bausch & Lomb to Neutral, Raises Price Target to $22 HC Wainwright & Co. analyst Yi Chen downgrades Bausch & Lomb (NYSE:BLCO) from Buy to Neutral and raises the price target from $21 to $22.
benzinga.com JP Morgan Maintains Neutral on Bausch & Lomb, Raises Price Target to $22 JP Morgan analyst Robbie Marcus maintains Bausch & Lomb (NYSE:BLCO) with a Neutral and raises the price target from $16 to $22.
benzinga.com RBC Capital Maintains Outperform on Bausch & Lomb, Raises Price Target to $23 RBC Capital analyst Douglas Miehm maintains Bausch & Lomb (NYSE:BLCO) with a Outperform and raises the price target from $21 to $23.
benzinga.com Wells Fargo Maintains Equal-Weight on Bausch & Lomb, Raises Price Target to $19 Wells Fargo analyst Larry Biegelsen maintains Bausch & Lomb (NYSE:BLCO) with a Equal-Weight and raises the price target from $18 to $19.
benzinga.com Bausch & Lomb Q3 Adj. EPS $0.34 Beats $0.22 Estimate, Sales $1.375B Beat $1.373B Estimate Bausch & Lomb (NYSE:BLCO) reported quarterly earnings of $0.34 per share which beat the analyst consensus estimate of $0.22 by 54.55 percent. This is a 88.89 percent increase over earnings of $0.18…
benzinga.com Bausch & Lomb Raises FY2026 Sales Guidance from $5.440B-$5.540B to $5.450B-$5.550B vs $5.496B Est Bausch & Lomb (NYSE:BLCO) raises FY2026 sales outlook from $5.440 billion-$5.540 billion to $5.450 billion-$5.550 billion vs $5.496 billion estimate.
